Skip to content

Gamma oryzanol Supplementation Study

Effects of gamma oryzanol supplementation on lipid profile, anabolic/catabolic hormones, circulating binding proteins and anthropometric changes in young males during resistance training

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013120715694N1
Enrollment
32
Registered
2014-05-05
Start date
2010-02-10
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

improving Anabolic and catabolic hormones alterations and blood lipid profile as well improving anthropometric measurements following resistance exercise in young males. Routine general health check-up of defined subpopulation

Interventions

Intervention 1: Supplement group: After first blood sampling, all the subjects performed acute heavy resistance protocol (AHRE) consisting of 6 sets of 10 repetitions with 80% 1RM, followed by second
Placebo
Supplement group: After first blood sampling, all the subjects performed acute heavy resistance protocol (AHRE) consisting of 6 sets of 10 repetitions with 80% 1RM, followed by second blood sampling.
Placebo group: After first blood sampling, all the subjects performed acute heavy resistance protocol (AHRE) consisting of 6 sets of 10 repetitions with 80% 1RM, followed by second blood sampling. Ea

Sponsors

Vice chancellor for research, University of Putra Malaysia
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 30 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: having no previous continuous resistance training (having resistance training for at least 20 minutes 2 to 3 times per week without stopping) during last 6 months before the study commencement; being males and age between 18-30; Exclusion criteria: A history of cardiovascular disease; Lactose intolerance, Diabetes mellitus, Cancer, Hypertension, Chronic obstructive pulmonary disease, Psychiatric disease; Any other serious life-threatening illness that required regular medical treatment; Alcohol intake of 15 drinks or more per week or at least 30 g/d <4d/week of recommended resistance exercise; <80% of provided supplement or placebo capsules; Smokers, or tobacco product consumers; Taking any weight lose drug or participating in any weight loss program or changing their diets for example vegetarian diet; Anti-inflammatory drugs, hormones supplements or any other supplements before (for a minimum of six months) or during the study period; Concurrent participation in other physical or exercise modalities

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Lipid profile. Timepoint: 9 weeks. Method of measurement: blood analysis.;Anabolic and catabolic hormones. Timepoint: 9 weeks. Method of measurement: blood analysis.

Secondary

MeasureTime frame
Anthropometric changes. Timepoint: 9 weeks. Method of measurement: Anthropocentric measurements.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaghar Eslami

University of Putra Malaysia

eslami_sr@yahoo.com0061451817195

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026